Pudong's institutional innovation explores new paths

A glimpse of Shanghai Pudong. Source: China News Service
Shanghai, April 18 (By CNS Reporter Li Shuzheng)
April 18, 2025 was the 35th anniversary of Pudong's development. This frontier of China's reform is using institutional innovation to solve the shortcomings of enterprises and industries, and explore new paths for China's continued communication with the outside world.
Not long ago, two old Volvo hydraulic pumps were transported from Pudong International Airport to the remanufacturing workshop of Volvo Construction Equipment (China) Co., Ltd. This was the first bonded remanufacturing business outside the customs special supervision area in the country in Pudong, and also meant the start of the "bonded remanufacturing 2.0" era.
Bonded remanufacturing refers to the transportation of old foreign parts to domestic factories in a duty-free manner for disassembly and inspection in accordance with strict quality standards, and the assembly of the usable parts and new parts into remanufactured products, which are then shipped abroad for reuse. Compared with bonded maintenance, bonded remanufacturing has higher technical requirements, and the performance of the finished product is no less than that of a new product; at the same time, the benefits are more significant, and the cost and raw material consumption is greatly reduced by reusing parts. "Spend 50% of the money, save 40% on energy consumption, recycle 70% of materials, and reduce 80% of pollution - this is the '5678' rule of remanufacturing." Chen Chaoping, vice president of service and accessories at Volvo Construction Equipment (China) Co., Ltd., said.
Developing bonded remanufacturing is not only in line with the development of the circular economy and China's "dual carbon" strategy requirements, but also an important measure to promote the high-quality development of China's manufacturing industry in the direction of green and low-carbon. In the past, remanufactured products were classified as old electromechanical products, so some remanufactured products were included in the prohibited import catalog and could not pass customs normally. In response to this issue, Pudong relied on institutional innovation to open up a new path for the pilot import of remanufactured products in key industries. Volvo Construction Equipment (China) Co., Ltd. has become the first pilot enterprise in the country in this field.
Chen Chaoping said that bonded remanufacturing is the core link of Volvo Construction Equipment's global strategy. Currently, only Pudong has a remanufacturing base that meets standards in the Asia-Pacific region. The new breakthrough in bonded remanufacturing has effectively strengthened the functional positioning of the base as a regional industrial hub. After bonded remanufacturing businesses outside the customs special supervision area are opened, it is expected that more types of engineering machinery will enter Shanghai from all over the world for "re-manufacturing" in the future.
Similarly, through cross-departmental collaborative supervision and facilitation of customs clearance for special items, Pudong has solved the problem of cross-border flow of cell therapy products and explored a new way for cell therapy products to travel overseas.
In March 2025, a lymphoma patient received an injection of Fosun Kerry's CAR-T cell therapy drug in a Hong Kong hospital. This is the first cross-border transportation and use of CAR-T cell drugs in the country, and it is also an important achievement of Shanghai's first joint supervision mechanism for the entry and exit of special biomedical items.
CAR-T cell therapy is an innovative cancer treatment method - by collecting the patient's own T cells, after in vitro transformation and amplification, they are re-injected into the patient's body to accurately identify and attack cancer cells. However, this therapy has extremely strict temperature and time requirements for the transportation of blood samples and finished products, and the entry and exit chain involves multiple departments.
In order to promote the international innovation and coordinated development of the biopharmaceutical industry, Pudong took the lead in piloting the establishment of a joint supervision mechanism for the entry and exit of special biopharmaceutical items, and formulated management measures to promote the transformation of the "white list" pilot to conditional pilot management.
Chen Xingrong, CEO of Fosun Kerry, said that the joint supervision mechanism for the entry and exit of special biopharmaceutical items provides an efficient and safe solution for the cross-border transportation and supervision of cell therapy products, and also opens up a new path for cooperation between the mainland and Hong Kong in the field of biopharmaceuticals.
For 35 years, Pudong has continued to transform corporate needs into institutional supply and promote the deep connection between innovative practices and international standards. "Pudong will bravely serve as a pioneer in the new era of reform and development, expanding the high-level opening process, exploring the way to build a new development pattern, and empowering high-quality development,” said Wu Jincheng, mayor of Shanghai Pudong New Area. (End)
相关阅读

- 
											
【异动股】Eden Innovations (ASX:EDE) 暴涨57%:美国数据中心客户OptiBlend kits订单持续放量
Eden Innovations Ltd (ASX股票代码:EDE) 过去两周进一步收到9份来自美国数据中心、总价值45.5万美元(约合69.8万澳元)的OptiBlend kits订单。
 

- 
											
Pudong's scientific and technological innovation breeds hard-core new technologies
The research and development of drugs that discover biological targets and therapeutic compounds by generative artificial intelligence (Generative AI) has entered the clinical trial stage. The “robot apprentice’s practical training collects data to feed back to the constructive system model…
 

- 
											
The 35th anniversary light show in Pudong, Shanghai outlines the future of innovation
On April 18, 2025, Pudong ushered in the 35th anniversary of district development in Shanghai.
 

- 
											
【异动股】 LBT Innovations(ASX:LBT)与药企巨头阿斯利康达成重大交易(+20%)
LBT Innovations(ASX:LBT)宣布与全球制药公司阿斯利康(AstraZeneca)签订重要合同,股价应声飙涨两成。
 

- 
											
移动支付平台PIL自2019年10月后首次复盘 股价大幅拉升
移动支付平台Peppermint Innovation Ltd (ASX: PIL)今日从2019年10月停盘后首次复盘,并发布公告称,公司进行了200万澳元的融资...
 

- 
											
亚马逊创新大会被取消 澳洲会展经济或遭更大打击
受新冠疫情影响,原定于3月末在悉尼国际会展中心举办的亚马逊创新大会(Amazon Innovation Day)被取消。
 

- 
											
亚洲坚果创新者通过全球首届澳洲坚果创新挑战赛展示全新
为了激励全球食品制造商并鼓励主要决策者将澳洲坚果更多地纳入他们的创新活动中,澳洲坚果产业营销项目(The Australian Macadamia Industry Marketing Program)打造出了一个全球首创的平台,以推动澳洲坚果的创新和新需求。
 

- 
											
【异动股】煤炭生产商New Hope Corporation (ASX:NHC)商品煤产量大幅增长 末期派息15澳分
New Hope Corporation Ltd (ASX股票代码:NHC)最新发布的财报显示,2025财年集团营收为17.96亿澳元,与上年基本持平;税后净利润同比微降,为4.39亿澳元。
 
免责声明:本网站信息仅供一般参考,不构成投资或财务建议。虽力求准确与完整,但不保证信息的准确性、完整性或时效性。投资有风险,决策前请咨询专业独立顾问。使用本网站即视为接受本免责声明。
热门点击
- 
									
									
- 【11.3】今日财经时讯及重要市场资讯
 
 - 
									
									
- Bubs Australia(ASX: BUB)FY26财年一季报出炉 营收增长30% 美国市场表现强劲 预计婴儿配方奶粉本年底获FDA批准
 
 - 
									
									
- Appen Limited(ASX: APX)季报观察:中国业务持续增长 年收入逾 1,000 万美元新项目全面投产
 
 - 
									
									
- 【11.4】今日财经时讯及重要市场资讯
 
 - 
									
									
- 【异动股】关键金属回收公司Metallium (ASX:MTM)股价持续高歌:年涨逾9倍 签下美国国防部合同 新近获高盛买入
 
 - 
									
									
- Theta Gold Mines Limited(ASX: TGM)加速推进TGME金矿厂建设 关键设备双球磨机已落实
 
 - 
									
									
- 【异动股】关键金属回收公司Metallium (ASX:MTM)股价持续高歌:年涨逾9倍 签下美国国防部合同 新近获高盛买入
 
 - 
									
									
- 穿越风暴巍然屹立:澳主权财富基金Future Fund投资策略揭晓
 
 - 
									
									
- 【异动股】年内涨逾22倍!锑矿股Locksley Resources (ASX:LKY) 获美国进出口银行1.91亿美元意向融资支持 股价再度飙升
 
 - 
									
									
- 【异动股】Resolution Minerals (ASX:RML)季报:美国“地区级”锑项目备受关注 成功吸引2700万澳元投资
 
 - 
									
									
- 麦格理研报:IDP教育、达美乐、IPH已具备“被收购”条件
 
 - 
									
									
- 住宅房地产风向扭转!NAB承诺提供600亿澳元助力开发商建设住房 帮助首次购房者购房
 
 - 
									
									
- 公寓之王Trigubo ff租金收入激增 美利通地产账面利润达2.22亿澳元
 
 - 
									
									
- 通胀压力再现 RBA澳储行维持现金利率3.60%不变
 
 - 
									
									
- 澳洲10位40岁以下最富有青年富豪揭晓 财富来源涉及AI、软件、网络游戏或加密货币
 
 

